The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour : A post-hoc analysis of the PRE-D trial. / Karstoft, Kristian; Ried-larsen, Mathias; Bruhn, Lea; Pilmark, Nanna Skytt; Hansen, Katrine Bagge; Persson, Frederik; Jørgensen, Marit Eika; Blond, Martin Bæk; Færch, Kristine.

In: Journal of Sports Sciences, Vol. 41, No. 18, 2023, p. 1687-1691.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Karstoft, K, Ried-larsen, M, Bruhn, L, Pilmark, NS, Hansen, KB, Persson, F, Jørgensen, ME, Blond, MB & Færch, K 2023, 'The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial', Journal of Sports Sciences, vol. 41, no. 18, pp. 1687-1691. https://doi.org/10.1080/02640414.2023.2291737

APA

Karstoft, K., Ried-larsen, M., Bruhn, L., Pilmark, N. S., Hansen, K. B., Persson, F., Jørgensen, M. E., Blond, M. B., & Færch, K. (2023). The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial. Journal of Sports Sciences, 41(18), 1687-1691. https://doi.org/10.1080/02640414.2023.2291737

Vancouver

Karstoft K, Ried-larsen M, Bruhn L, Pilmark NS, Hansen KB, Persson F et al. The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial. Journal of Sports Sciences. 2023;41(18):1687-1691. https://doi.org/10.1080/02640414.2023.2291737

Author

Karstoft, Kristian ; Ried-larsen, Mathias ; Bruhn, Lea ; Pilmark, Nanna Skytt ; Hansen, Katrine Bagge ; Persson, Frederik ; Jørgensen, Marit Eika ; Blond, Martin Bæk ; Færch, Kristine. / The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour : A post-hoc analysis of the PRE-D trial. In: Journal of Sports Sciences. 2023 ; Vol. 41, No. 18. pp. 1687-1691.

Bibtex

@article{c3dda65b8361403faee65976981353cf,
title = "The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour: A post-hoc analysis of the PRE-D trial",
abstract = "Perceived physical exertion is increased when exercise is performed on metformin treatment, but the clinical relevance of this is unknown. In this post hoc analysis of a randomized, controlled trial, we investigated whether metformin treatment was associated with lower levels of free-living physical activity.   Ninety individuals with overweight/obesity (BMI>25 m2/kg) and HbA1c-defined prediabetes (39-47 mmol/mol) were randomized to treatment with dapagliflozin (SGLT2-inhibitor; 10 mg once daily, n=30), metformin (850 mg twice daily, n=30) or no treatment (control, n=30) for 13 weeks in a parallel-group, open-label trial. Before (baseline), during (6 weeks) and immediately after (13 weeks) cessation of treatment, a 6-day assessment of physical activity and sedentary behaviour was performed using accelerometer-based physical activity monitors. Intention-to-treat analyses revealed no within-group changes or differences in change between the groups for any measures of physical activity or sedentary behaviour at neither 6 nor 13 weeks. Short-term metformin treatment does not reduce free-living physical activity level in individuals with overweight/obesity and HbA1c-defined prediabetes.",
author = "Kristian Karstoft and Mathias Ried-larsen and Lea Bruhn and Pilmark, {Nanna Skytt} and Hansen, {Katrine Bagge} and Frederik Persson and J{\o}rgensen, {Marit Eika} and Blond, {Martin B{\ae}k} and Kristine F{\ae}rch",
year = "2023",
doi = "10.1080/02640414.2023.2291737",
language = "English",
volume = "41",
pages = "1687--1691",
journal = "Journal of Sports Sciences",
issn = "0264-0414",
publisher = "Routledge",
number = "18",

}

RIS

TY - JOUR

T1 - The effect of metformin treatment on volumes of free-living physical activity and sedentary behaviour

T2 - A post-hoc analysis of the PRE-D trial

AU - Karstoft, Kristian

AU - Ried-larsen, Mathias

AU - Bruhn, Lea

AU - Pilmark, Nanna Skytt

AU - Hansen, Katrine Bagge

AU - Persson, Frederik

AU - Jørgensen, Marit Eika

AU - Blond, Martin Bæk

AU - Færch, Kristine

PY - 2023

Y1 - 2023

N2 - Perceived physical exertion is increased when exercise is performed on metformin treatment, but the clinical relevance of this is unknown. In this post hoc analysis of a randomized, controlled trial, we investigated whether metformin treatment was associated with lower levels of free-living physical activity.   Ninety individuals with overweight/obesity (BMI>25 m2/kg) and HbA1c-defined prediabetes (39-47 mmol/mol) were randomized to treatment with dapagliflozin (SGLT2-inhibitor; 10 mg once daily, n=30), metformin (850 mg twice daily, n=30) or no treatment (control, n=30) for 13 weeks in a parallel-group, open-label trial. Before (baseline), during (6 weeks) and immediately after (13 weeks) cessation of treatment, a 6-day assessment of physical activity and sedentary behaviour was performed using accelerometer-based physical activity monitors. Intention-to-treat analyses revealed no within-group changes or differences in change between the groups for any measures of physical activity or sedentary behaviour at neither 6 nor 13 weeks. Short-term metformin treatment does not reduce free-living physical activity level in individuals with overweight/obesity and HbA1c-defined prediabetes.

AB - Perceived physical exertion is increased when exercise is performed on metformin treatment, but the clinical relevance of this is unknown. In this post hoc analysis of a randomized, controlled trial, we investigated whether metformin treatment was associated with lower levels of free-living physical activity.   Ninety individuals with overweight/obesity (BMI>25 m2/kg) and HbA1c-defined prediabetes (39-47 mmol/mol) were randomized to treatment with dapagliflozin (SGLT2-inhibitor; 10 mg once daily, n=30), metformin (850 mg twice daily, n=30) or no treatment (control, n=30) for 13 weeks in a parallel-group, open-label trial. Before (baseline), during (6 weeks) and immediately after (13 weeks) cessation of treatment, a 6-day assessment of physical activity and sedentary behaviour was performed using accelerometer-based physical activity monitors. Intention-to-treat analyses revealed no within-group changes or differences in change between the groups for any measures of physical activity or sedentary behaviour at neither 6 nor 13 weeks. Short-term metformin treatment does not reduce free-living physical activity level in individuals with overweight/obesity and HbA1c-defined prediabetes.

U2 - 10.1080/02640414.2023.2291737

DO - 10.1080/02640414.2023.2291737

M3 - Journal article

C2 - 38053246

VL - 41

SP - 1687

EP - 1691

JO - Journal of Sports Sciences

JF - Journal of Sports Sciences

SN - 0264-0414

IS - 18

ER -

ID: 375203578